TY - JOUR
T1 - Wearable electronic devices for glaucoma monitoring and therapy
AU - Zhang, Wanqing
AU - Huang, Lingling
AU - Weinreb, Robert N.
AU - Cheng, Huanyu
N1 - Funding Information:
H.C. would like to acknowledge the supports from the National Science Foundation (NSF) (Grant No. ECCS-1933072), the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R61HL154215, the Doctoral New Investigator grant from the American Chemical Society Petroleum Research Fund (59021-DNI7), and Penn State University. The partial support from the Center for Biodevices, the College of Engineering, and the Center for Security Research and Education at Penn State is also acknowledged. Also, supported in part by an unrestricted grant from Research to Prevent Blindness (New York, NY), and R01MD014850 from the National Institute on Minority Health and Health Disparities (R.N. W.).
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/12/15
Y1 - 2021/12/15
N2 - Glaucoma is a leading cause of irreversible blindness worldwide, which is estimated to affect approximately 112 million people by 2040. Elevated intraocular pressure (IOP) is the most important risk factor for glaucoma, as well as the primary target for the treatment. Current therapies aim at IOP reduction to prevent the disease progression. The accurate and real-time measurement of IOP is therefore critical to evaluate treatment response and guide medical decisions. However, IOP fluctuates throughout the 24-hour cycle with different patterns from day to day in the same individual and also different patterns among individuals. The current clinical practice typically captures a single IOP measurement during “in-office hours”, and this is insufficient for disease monitoring. With the development of wearable electronic devices, a variety of IOP monitoring devices provide a unique potential for continuous IOP monitoring. In addition to IOP monitoring for glaucoma management, this mini-review also summarizes novel drug delivery devices for treating glaucoma. Because certain types of glaucoma do not show elevated IOP, we also discuss the potential to incorporate biomarker detection with IOP measurement for more accurate and reliable glaucoma diagnostics and therapies.
AB - Glaucoma is a leading cause of irreversible blindness worldwide, which is estimated to affect approximately 112 million people by 2040. Elevated intraocular pressure (IOP) is the most important risk factor for glaucoma, as well as the primary target for the treatment. Current therapies aim at IOP reduction to prevent the disease progression. The accurate and real-time measurement of IOP is therefore critical to evaluate treatment response and guide medical decisions. However, IOP fluctuates throughout the 24-hour cycle with different patterns from day to day in the same individual and also different patterns among individuals. The current clinical practice typically captures a single IOP measurement during “in-office hours”, and this is insufficient for disease monitoring. With the development of wearable electronic devices, a variety of IOP monitoring devices provide a unique potential for continuous IOP monitoring. In addition to IOP monitoring for glaucoma management, this mini-review also summarizes novel drug delivery devices for treating glaucoma. Because certain types of glaucoma do not show elevated IOP, we also discuss the potential to incorporate biomarker detection with IOP measurement for more accurate and reliable glaucoma diagnostics and therapies.
UR - http://www.scopus.com/inward/record.url?scp=85117600389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117600389&partnerID=8YFLogxK
U2 - 10.1016/j.matdes.2021.110183
DO - 10.1016/j.matdes.2021.110183
M3 - Article
AN - SCOPUS:85117600389
SN - 0261-3069
VL - 212
JO - International Journal of Materials in Engineering Applications
JF - International Journal of Materials in Engineering Applications
M1 - 110183
ER -